推荐产品
等級
certified reference material
品質等級
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商／商標名
Cerilliant®
濃度
100 μg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
clinical testing
格式
single component solution
儲存溫度
−20°C
SMILES 字串
OCc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4-n12
InChI
1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2
InChI 密鑰
QHSMEGADRFZVNE-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
α-羟基咪达唑仑是苯二氮咪达唑仑在尿液和血液中的活性主要代谢产物。咪达唑仑以Dormicum、Hypnovel®和Versed商品名销售，并已作为治疗失眠和惊厥的镇静剂和治疗方法。该认证的加标溶液®适合用作校准品或对照品中的原材料，用于从法医分析和临床毒理学到尿液药物测试的各种LC/MS或GC/MS应用。
應用
- α-Hydroxymidazolam solution in pharmacokinetic studies: The application of α-Hydroxymidazolam solution is crucial in pharmacokinetic research to study the metabolism of midazolam, particularly its phase I metabolic pathways, providing essential data on the drug′s biotransformation and clearance rates in humans (Bourget et al., 1996).
- α-Hydroxymidazolam as a benzodiazepine metabolite standard: Utilized as a benzodiazepine metabolite standard, α-Hydroxymidazolam aids in the accurate measurement of midazolam and its metabolites in plasma using high-performance liquid chromatography, essential for ensuring dosing efficacy and safety in clinical settings (Lee and Charles, 1996).
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Hypnovel is a registered trademark of Hoffman-LaRoche & Co. AG
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
相關產品
产品编号
说明
价格
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
49.5 °F - closed cup
閃點（°C）
9.7 °C - closed cup
其他客户在看
Kristin Samuelsson et al.
Xenobiotica; the fate of foreign compounds in biological systems, 42(11), 1128-1137 (2012-05-31)
The pharmacokinetics and biotransformation of midazolam were investigated following single oral doses of 0.1, 1 and 10 mg/kg to chimeric mice with humanised livers (PXB mice) and to severe combined immunodeficient (SCID) mice used as controls. Pharmacokinetic analysis, on whole
Varun Garg et al.
Journal of clinical pharmacology, 52(10), 1566-1573 (2011-12-14)
In this open-label study, 24 healthy volunteers received a single intravenous (IV) dose of 0.5 mg of midazolam on day 1 and a single oral dose each of 2 mg of midazolam and 0.5 mg of digoxin on day 3.
Stephanie Katzenmaier et al.
European journal of clinical pharmacology, 66(11), 1137-1141 (2010-08-04)
Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam
Camilla Svanström et al.
Journal of pharmaceutical and biomedical analysis, 58, 71-77 (2011-10-14)
The metabolic conversion of midazolam (MDZ) to its main metabolite 1'-hydroxy-midazolam (1-OH-MDZ) can be used as a probe drug for cytochrome P450 3A (CYP3A) activity. A sensitive method for the simultaneous determination of MDZ and its metabolite 1-OH-MDZ in human
Leonie Fetzner et al.
Journal of clinical pharmacology, 51(8), 1223-1232 (2010-12-15)
Several studies investigating the interaction of honey and drug-metabolizing enzymes showed controversial results, with some suggesting that honey induces CYP3A-mediated metabolism in mammals and humans. This clinical trial was conducted to determine the effect of repeated honey administration on human
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门